IP Library Granted Patent US 7,872,126
Granted Patent B2
US 7,872,126 · App. 11/527,691 · Granted Jan 18, 2011

Tetrahydroquinoline derivatives and a process for preparing the same

Assignee: Mitsubishi Tanabe Pharma Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,872,126
App. No.
11/527,691
Granted
Jan 18, 2011
Kind
B2
Abstract

A novel compound of the formula (I): wherein R 1 is alkoxycarbonyl or the like, R 2 is alkyl or the like; R 3 is hydrogen or the like; R 4 is alkylene or the like; R 5 is optionally substituted heterocyclic group; R 6 , R 7 , R 8 and R 9 are independently hydrogen; alkyl, alkoxy, or the like; R 10 is optionally substituted aromatic ring, or the like; or a pharmaceutically acceptable salt thereof, which has an inhibitory activity against cholesteryl ester transfer protein (CETP).

Claims (85)

1. A compound of the formula (I):

wherein R 1 is an alkoxycarbonyl group or an alkoxycarbonyl group substituted by 1 to 5 substituents selected independently from a carboxyl group, an alkoxycarbonyl group, a halogen atom, a hydroxy group and a cycloalkyl group;

R 2 is an alkyl group;

R 3 is a hydrogen atom;

R 4 is an alkylene group;

R 5 is a group of the formula:

R 10 is a phenyl group substituted by 1 to 3 substituents selected from a cyano group, an alkyl group, an alkyl group substituted by one or more halogen atom, and an alkoxy group;

Ring A is a pyrimidinyl group or a pyridyl group;

R 11 is an alkoxy group substituted by a carboxyl group, a cyano group, a hydroxy group, an alkoxy group, an alkylthio group or an alkylsulfonyl group; a mono- or di-alkylamino group; or a mono- or di-alkylamino group substituted by an alkoxy group;

R 6 and R 9 each are a hydrogen atom;

R 7 is an alkyl group, an alkyl group substituted by one or more halogen atom, an alkoxy group, or a mono- or di-alkylamino group; and

R 8 is a hydrogen atom;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein R 1 is an ethoxycarbonyl group, a hydroxyethoxycarbonyl group, a 2-fluoroethoxycarbonyl group, a 2,2-difluoroethoxycarbonyl group or a 2,2,2-trifluoroethoxycarbonyl group; R 2 is an ethyl group; R 10 is a phenyl group substituted by 1 to 2 substituents selected from a cyano group, a trifluoromethyl group and a methoxy group; and R 7 is a trifluoromethyl group or a methoxy group.

3. The compound of claim 1 , wherein R 1 is a carboxy(C 2-l0 alkoxy)carbonyl group or an alkoxycarbonyl(C 2-10 alkoxy)carbonyl group; R 2 is an ethyl group; R 10 is a phenyl group substituted by 1 to 2 substituents selected from a cyano group, a trifluoromethyl group and a methoxy group; and R 7 is a trifluoromethyl group or a methoxy group.

4. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

(2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]-(5-{[methyl-(2-methoxyethyl)]-amino}pyrimidin-2-yl)]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-carboxypropoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-carboxybutoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(5-carboxypentyloxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-carboxyethoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

(2R,4S)-4-{(3-Cyano-5-trifluoromethylbenzyl)-[5-(4-carboxybutoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-carboxypropoxy)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-carboxypropoxy)pyrimidin-2-yl]}amino-2-ethyl-6-dimethylamino-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-carboxypropoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2,2,2-trifluoroethyl ester; and

(2R,4S)-4-{(3-Cyano-5-trifluoromethylbenzyl)-[5-(3-carboxypropoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2,2,2-trifluoroethyl ester;

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein the compound is selected from the group consisting of:

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 3-carboxypropyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 4-carboxybutyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxy-2-methylpropyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxy-2-methylpropyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 5-carboxypentyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-cyanopropoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 3-carboxypropyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-cyanopropoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 4-carboxybutyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-cyanopropoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxy-2-methylpropyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-cyanopropoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 5-carboxypentyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-(5-dimethylaminopyrimidin-2-yl)}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 3-carboxypropyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-(5-dimethylaminopyrimidin-2-yl)}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 4-carboxybutyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-(5-dimethylaminopyrimidin-2-yl)}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxy-2-methylpropyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-(5-dimethylaminopyrimidin-2-yl)}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 5-carboxypentyl ester;

(2R,4S)-4-{(3-Cyano-5-trifluoromethylbenzyl)-[5-(2-methoxyethoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-{(3-Cyano-5-trifluoromethylbenzyl)-[5-(2-methoxyethoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 3-carboxypropyl ester;

(2R,4S)-4-{(3-Cyano-5-trifluoromethylbenzyl)-[5-(2-methoxyethoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 4-carboxybutyl ester;

(2R,4S)-4-{(3-Cyano-5-trifluoromethylbenzyl)-[5-(2-methoxyethoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxy-2-methylpropyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-hydroxyethoxy)pyridin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxy-2-methylpropyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyridin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyridin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 3-carboxypropyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyridin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 4-carboxybutyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2-methoxyethoxy)pyridin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxy-2-methylpropyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-cyanopropoxy)pyridin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-(5-dimethylaminopyridin-2-yl) }amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-(5-dimethylaminopyridin-2-yl)}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 3-carboxypropyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-(5-dimethylaminopyridin-2-yl)}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 4-carboxybutyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-(5-dimethylaminopyridin-2-yl)}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxy-2-methylpropyl ester;

(2R,4S)-4-{(3-Cyano-5-trifluoromethylbenzyl)-[5-(2-methoxyethoxy)pyridin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxyethyl ester; and

(2R,4S)-4-{(3-Cyano-5-trifluoromethylbenzyl)-[5-(2-methoxyethoxy)pyrimidin-2-yl]}amino-2-ethyl-6,7-ethylenedioxy-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxyethyl ester;

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the compound is selected from the group consisting of:

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(3-hydroxypropoxy)pyrimidin-2-yl]}amino -2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxy-2-methylpropyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5- (2,3-dihydroxypropoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxy-2-methylpropyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5- (3-hydroxypropoxy)pyrimidin-2-yl]}amino -2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(2,3-dihydroxypropoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro -2H-quinoline-1-carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-{(3-Cyano-5-trifluoromethylbenzyl)-[5-(2-hydroxyethoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxy-2-methylpropyl ester;

(2R,4S)-4-{(3-Cyano-5-trifluoromethylbenzyl)-[5-(2-methoxyethoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxy-2-methylpropyl ester;

(2R,4S)-4-{[5-(3-Cyanopropoxy)pyrimidin-2-yl]-(3-Cyano-5-trifluoromethylbenzyl)}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxy-2-methylpropyl ester;

(2R,4S)-4-{(3-Cyano-5-trifluoromethylbenzyl)-[5-(2-hydroxyethoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-{(3-Cyano-5-trifluoromethylbenzyl)-[5-(2-methoxyethoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-{[5-(3-Cyanopropoxy)pyrimidin-2-yl]-(3-Cyano-5-trifluoromethylbenzyl)}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-[(3-Cyano-5-trifluoromethylbenzyl)-(5-dimethylaminopyrimidin-2-yl)]amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-([3,5-Bis(trifluoromethyl)benzyl]-{5-[(ethyl-methyl)amino]pyrimidin-2-yl})amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-(5-diethylaminopyrimidin-2-yl)}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxyethyl ester;

(2R,4S)-4-([3,5-Bis(trifluoromethyl)benzyl]-{5-[(ethyl-methyl)amino]pyrimidin-2-yl})amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxy-2-methylpropyl ester; and

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-(5-diethylaminopyrimidin-2-yl)}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-carboxy-2-methylpropyl ester;

or a pharmaceutically acceptable salt thereof.

7. A process for preparing a tetrahydroquinoline derivative of the formula (I):

wherein the symbols R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 have the same meaning as defined in claim 1 , which comprises condensing a compound of the formula (II):

wherein each symbol has the same meaning as defined above with a compound of the formula (III):

R 10 —R 4 —Z 1   (III)

wherein Z 1 is a leaving group and the other symbols have the same meaning as defined above.

8. A pharmaceutical composition, which comprises as an active ingredient a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

9. The compound of claim 2 , wherein R 1 is an ethoxycarbonyl group or a hydroxyethoxycarbonyl group; R 2 is an ethyl group; R 10 is a phenyl group substituted by 1 to 2 substituents selected from cyano group, trifluoromethyl group and methoxy group; R 7 is a trifluoromethyl group or a methoxy group.

10. The compound according to claim 1 , which is (2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(4-carboxybutoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, or a pharmaceutically acceptable salt thereof.

11. The compound according to claim 1 , which is (2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5(3-carboxypropoxy)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, or a pharmaceutically acceptable salt thereof.

Assignments (4)
CHANGE OF NAME Recorded Jun 9, 2022
From: DEZIMA PHARMA B.V.
To: NEWAMSTERDAM PHARMA B.V.
Reel/Frame 060379/0089 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2016
From: MITSUBISHI TANABE PHARMA CORPORATION
To: DEZIMA PHARMA B.V.
Reel/Frame 040800/0614 →
CHANGE OF NAME Recorded Nov 1, 2007
From: TANABE SEIYAKU CO., LTD.
To: MITSUBISHI TANABE PHARMA CORPORATION
Reel/Frame 020053/0662 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2006
From: KUBOTA, HITOSHI; SUGAHARA, MASAKATSU; FURUKAWA, MARIKO; TAKANO, MAYUMI; MOTOMURA, DAISUKE
To: TANABE SEIYAKU CO., LTD.
Reel/Frame 018355/0851 →
Priority Claims (1)
JP 2004-109550 · Apr 2, 2004 · national
Continuity (3)
Continuation In Part PCTJP200500689400 · Apr 1, 2005
Provisional Application 6072044800 · Sep 27, 2005
Related Publication 20070082896A1 · Apr 12, 2007